Author: Sivalingam, Thivya; Inusa, Baba; Doyle, Pat; Otengâ€Ntim, Eugene
Title: COVIDâ€19 and the pulmonary complications of sickle cell disease Cord-id: 5lnh4lfr Document date: 2020_10_8
ID: 5lnh4lfr
Snippet: Sickle cell disease (SCD) patients are commonly affected by pulmonary complications such as acute chest syndrome (ACS), pulmonary embolism (PE) and pneumonia that contribute to significant mortality risks. With a greater susceptibility to infection, they are deemed to be vulnerable patients during the current COVIDâ€19 pandemic. In emerging small case studies of SCD patients with COVIDâ€19 and further complicated by pneumonia, ACS, and/or PE, the clinical benefits of early exchange transfusion
Document: Sickle cell disease (SCD) patients are commonly affected by pulmonary complications such as acute chest syndrome (ACS), pulmonary embolism (PE) and pneumonia that contribute to significant mortality risks. With a greater susceptibility to infection, they are deemed to be vulnerable patients during the current COVIDâ€19 pandemic. In emerging small case studies of SCD patients with COVIDâ€19 and further complicated by pneumonia, ACS, and/or PE, the clinical benefits of early exchange transfusion and Tocilizumab are evident. However, further clinical trials and larger cohort studies are essential to evaluate effective diagnostic and management options for this highâ€risk group.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date